[go: up one dir, main page]

PL2976360T3 - Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego - Google Patents

Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego

Info

Publication number
PL2976360T3
PL2976360T3 PL14714586T PL14714586T PL2976360T3 PL 2976360 T3 PL2976360 T3 PL 2976360T3 PL 14714586 T PL14714586 T PL 14714586T PL 14714586 T PL14714586 T PL 14714586T PL 2976360 T3 PL2976360 T3 PL 2976360T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
antibodies against
therapy involving
involving antibodies
Prior art date
Application number
PL14714586T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Original Assignee
Astellas Pharma Inc.
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/000817 external-priority patent/WO2014146672A1/en
Application filed by Astellas Pharma Inc., Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Astellas Pharma Inc.
Publication of PL2976360T3 publication Critical patent/PL2976360T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14714586T 2013-03-18 2014-03-17 Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego PL2976360T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2013/000817 WO2014146672A1 (en) 2013-03-18 2013-03-18 Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP14714586.6A EP2976360B1 (en) 2013-03-18 2014-03-17 Therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2014/000719 WO2014146778A1 (en) 2013-03-18 2014-03-17 Therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
PL2976360T3 true PL2976360T3 (pl) 2020-05-18

Family

ID=54867420

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14714586T PL2976360T3 (pl) 2013-03-18 2014-03-17 Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego

Country Status (4)

Country Link
EP (2) EP2976360B1 (pl)
HR (1) HRP20200019T1 (pl)
PL (1) PL2976360T3 (pl)
SI (1) SI2976360T1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
CN113817061B (zh) * 2019-01-15 2022-11-04 浙江道尔生物科技有限公司 一种抗cld18a2单域抗体及其抗肿瘤用途
KR20230027269A (ko) * 2020-06-23 2023-02-27 안텐진 바이올로직스 리미티드 클라우딘 관련 질환을 치료하기 위한 항체 및 방법
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
US20240092892A1 (en) * 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP1354034B8 (en) 2000-11-30 2008-06-18 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer

Also Published As

Publication number Publication date
SI2976360T1 (sl) 2020-04-30
EP3670537A1 (en) 2020-06-24
EP2976360A1 (en) 2016-01-27
HRP20200019T1 (hr) 2020-04-03
EP2976360B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
IL239981A0 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
PT3033086T (pt) Terapia de combinação para o tratamento de cancro
PL3254695T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
GB201322626D0 (en) Combined preparations for the treatment of cancer
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
HK40092402A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40110865A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40087661A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
GB201317564D0 (en) Therapeutic for the treatment of Lung Cancer